George Gourzoulidis
Overview
Explore the profile of George Gourzoulidis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tzanetakos C, Psarra M, Kotsis I, Gourzoulidis G
Value Health Reg Issues
. 2025 Feb;
46:101091.
PMID: 39954537
Objectives: This study aimed to evaluate the cost-effectiveness of upadacitinib in patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response, lost response, or were...
2.
Angelopoulos P, Markopoulos T, Lazarou L, Skolarikos A, Stamatakos P, Papadopoulos G, et al.
Curr Oncol
. 2025 Jan;
32(1).
PMID: 39851934
Background: While the clinical application of SII-ONCO-Bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) is well established in Greece, there is a lack of real-world data on its effectiveness and...
3.
Gourzoulidis G, Tzanetakos C, Solakidi A, Markatis E, Detsis M, Mendes D, et al.
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591135
Background/objectives: To evaluate the health benefits, costs, and cost-effectiveness of vaccination with bivalent respiratory syncytial virus stabilized prefusion F vaccine (RSVpreF) for the prevention of lower respiratory tract disease caused...
4.
Gourzoulidis G, Solakidi A, Psarra M, Nikitopoulou E, Tzanetakos C
Clin Drug Investig
. 2023 Dec;
44(1):59-69.
PMID: 38104048
Background And Objective: Ankylosing spondylitis is a chronic, progressive, inflammatory, multidimensional, musculoskeletal disease primarily involving the axial skeleton. In addition, ankylosing spondylitis is associated with increased morbidity and mortality, significantly...
5.
Gourzoulidis G, Zisimopoulou O, Liavas A, Tzanetakos C
Expert Rev Pharmacoecon Outcomes Res
. 2023 Nov;
24(3):375-385.
PMID: 37997764
Objectives: To evaluate the cost-effectiveness of lorlatinib compared to 1 generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2 generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+...
6.
Gourzoulidis G, Barmpouni M, Kossyvaki V, Vietri J, Tzanetakos C
Front Public Health
. 2023 Oct;
11:1229524.
PMID: 37841729
Objective: Higher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the...
7.
Warren S, Barmpouni M, Kossyvaki V, Gourzoulidis G, Perdrizet J
Vaccines (Basel)
. 2023 Aug;
11(8).
PMID: 37631937
In June 2010, Greece introduced the 13-valent pneumococcal conjugate vaccine (PCV13) for pediatric vaccination and has since observed a large decrease in pneumococcal disease caused by these vaccine serotypes, yet...
8.
Tzanetakos C, Gourzoulidis G
Value Health Reg Issues
. 2023 Apr;
36:18-26.
PMID: 37004314
Objectives: This study aimed to systematically review the use of cost-effectiveness (CE) threshold for evaluating pharmacological interventions in Greece. Methods: A systematic search of PubMed and ScienceDirect was conducted between...
9.
Gourzoulidis G, Koulentaki M, Kattamis A, Bouzani M, Giatra C, Chotzagiannoglou V, et al.
Clin Drug Investig
. 2022 Dec;
43(2):151.
PMID: 36580214
No abstract available.
10.
Gourzoulidis G, Koulentaki M, Kattamis A, Bouzani M, Giatra C, Chotzagiannoglou V, et al.
Clin Drug Investig
. 2022 Oct;
42(11):999-1008.
PMID: 36227415
Background And Objective: Acute lymphoblastic leukemia (ALL) is an acute, rapidly progressing and life-threatening form of cancer involving immature lymphocytes called lymphoblasts. ALL is the most common subtype of leukemia...